Abstract

Radiotherapy is routinely used for the treatment of head and neck squamous cell carcinoma (HNSCC). However, the therapeutic efficacy is usually reduced by acquired radioresistance and locoregional recurrence. In this study, The Cancer Genome Atlas (TCGA) analysis showed that radiotherapy upregulated the miR-182/96/183 cluster and that miR-182 was the most significantly upregulated. Overexpression of miR-182-5p enhanced the radiosensitivity of HNSCC cells by increasing intracellular reactive oxygen species (ROS) levels, suggesting that expression of the miR-182 family is beneficial for radiotherapy. By intersecting the gene targeting results from three microRNA target prediction databases, we noticed that sestrin2 (SESN2), a molecule resistant to oxidative stress, was involved in 91 genes predicted in all three databases to be directly recognized by miR-182-5p. Knockdown of SESN2 enhanced radiation-induced ROS and cytotoxicity in HNSCC cells. In addition, the radiation-induced expression of SESN2 was repressed by overexpression of miR-182-5p. Reciprocal expression of the miR-182-5p and SESN2 genes was also analyzed in the TCGA database, and a high expression of miR-182-5p combined with a low expression of SESN2 was associated with a better survival rate in patients receiving radiotherapy. Taken together, the current data suggest that miR-182-5p may regulate radiation-induced antioxidant effects and mediate the efficacy of radiotherapy.

Highlights

  • IntroductionHead and neck squamous cell carcinoma (HNSCC) was responsible for

  • We further investigated whether high expression of these microRNAs influenced the survival rate of head and neck squamous cell carcinoma (HNSCC) patients, as the miR-182/96/183 cluster was regarded as an oncogenic cluster in most cancers [49]

  • A regulatory pathway linking miR-182-5p and the antioxidant molecule SESN2 was demonstrated by current data

Read more

Summary

Introduction

Head and neck squamous cell carcinoma (HNSCC) was responsible for. 890,000 cases and 450,000 deaths in 2018, and these numbers are expected to increase by approximately one million new cases annually by 2030 [1,2]. HNSCC is ranked as the sixth most common human cancer in a cross-country study [3]. HNSCC is notorious for its high recurrence rate and local invasion, which leads to its high mortality [4,5]. Adjuvant radiotherapy and chemotherapy are the primary strategies for the treatment of HNSCC, the development of radioresistance has been reported to be accompanied by Antioxidants 2021, 10, 1808.

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.